watch
Tekla Healthcare Opportunities Fund

Tekla Healthcare Opportunities Fund

Sector: Unit Investment Trusts, Face-Amount Certificate Offices, and Closed-End Management Investment Offices Region: MA, United States


: | NYSE MKT: THQ


Similar to: The European Equity Fund, Inc., BlackRock MuniYield Arizona Fund, Inc., Nuveen Quality Preferred Income Fund 2

Tekla Healthcare Opportunities Fund ("THQ") is a non-diversified closed-end fund traded on the New York Stock Exchange under the ticker THQ. THQ invests primarily in the healthcare industry. The Fund's objective is to seek current income and long-term capital appreciation through investing in companies engaged in the healthcare industry, including equity securities, debt securities and pooled investment vehicles.

Executives

DANIEL R. OMSTEAD, PH.D., President and Chief Executive Officer
Dr. Omstead is also President of TCM and the Funds. Dr. Omstead joined TCM in October 2000.

Previously, Dr. Omstead was President and CEO of Reprogenesis, Inc. a private development stage biotech company developing therapies in the field of regenerative medicine. In 2000, Reprogenesis was merged with two other biotech companies to form Curis, Inc. Before joining Reprogenesis, Dr. Omstead was Senior Vice President, Research and Development at Cytotherapeutics, Inc a public biotech company that developed CNS therapies. Prior to entering the biotech industry, Dr. Omstead was employed for fourteen years in the pharmaceutical industry at Ortho Pharmaceutical Corporation and at the R.W. Johnson Pharmaceutical Research Institute, both divisions of Johnson & Johnson and at Merck Sharpe and Dohme Research Laboratories, a division Merck and Company, Inc. While at J&J, he participated in the development of Orthoclone OKT3™, Eprex™/Procrit™ and other biological products. While at Merck, he worked on the development of Recombivax™, Mefoxin™, Heartguard™ and other traditional drug products. Dr. Omstead holds Doctoral and Master’s Degrees in Chemical Engineering and Applied Chemistry from Columbia University and a B.S. degree in Civil Engineering from Lehigh University.

Dr. Omstead is a member of the team responsible for making investments on behalf of the Funds and has overall investment decision responsibility. Dr. Omstead has over fifteen years of investment experience. Dr. Omstead is also responsible for the overall strategic direction and operations of TCM.
JASON C. AKUS, M.B.A, M.D., Senior Vice President, Research
Dr. Akus joined TCM in July of 2001 after graduating from Tufts University. During medical school, Jason consulted for a variety of Healthcare IT companies Dr. Akus holds a B.S. in Mathematics and an M.D. and M.B.A. from Tufts University.

Dr. Akus is responsible for investment research and due diligence in the biotechnology, medical device, and diagnostic areas and serves as a member of the team responsible for making investments on behalf of the Funds. Dr. Akus has over fifteen years of investment experience.
TIMOTHY GASPERONI, M.B.A, PH.D., Senior Vice President, Research
Dr. Gasperoni joined TCM in March of 2015. Previously, he was a Senior Analyst and Founding Member of Sabby Capital, a public and private equity fund focused on biotechnology and medical devices. Dr. Gasperoni was head of Sabby’s research function and led the firm’s venture investment arm. Previously, Dr. Gasperoni was a Partner and Senior Analyst at Crosswind Investments, LLC, a spin-off of Cowen & Co that managed small- and mid-cap growth funds. During Dr. Gasperoni’s tenure at the firm, the funds outperformed their respective benchmarks by over 2500 basis points. Prior to Crosswind, Dr. Gasperoni was the Senior Analyst at Andesite, LLC, a healthcare-dedicated long-short fund. He led the firm’s research function and was responsible for all syndicate transaction. Prior to his career in financial services, Dr. Gasperoni served in consulting, operating, and scientific roles in the biopharmaceutical industry. Dr. Gasperoni holds a B.A. from Swarthmore College, an M.A. from the University of Pennsylvania, a Ph.D. in Neuroscience from UCLA, and an MBA from MIT.

Dr. Gasperoni is responsible for investment research and due diligence in the biotechnology, medical device, and diagnostic areas and serves as a member of the team responsible for making investments on behalf of the Funds.
CHRISTIAN M. RICHARD, M.S, M.B.A., Senior Vice President, Research
Christian Richard joined TCM in March of 2015. Previously, Mr. Richard was a Partner/Head of Research for Merlin Biomed Private Equity/Merlin Nexus for 12 years. Merlin Nexus is a cross-over life sciences fund focused on negotiated transactions in both late-stage private and public companies. Prior to Merlin Nexus, Mr. Richard spent almost five years in the Allergy/Immunology Group at the Schering-Plough Research Institute. He has a B.S. in Cellular and Molecular Biology from Purchase College and both an M.S. in Biochemistry and an M.B.A. in Finance from NYU.

Mr. Richard is responsible for investment research and due diligence in the biotechnology, medical device, and diagnostic areas and serves as a member of the team responsible for making investments on behalf of the Funds.
WILLIAM R. HITE, CFA®, Vice President, Research
William Hite joined TCM in March of 2015. Previously, he was an Associate Analyst at Columbia Management where he covered Global Healthcare. Prior to Columbia Management, Mr. Hite was an Associate Analyst at Lazard Capital Markets, focusing on Biotechnology, Life Science Tools and Diagnostics. Mr. Hite has also previously worked at Leerink Partners where he focused on Healthcare Investing and Binary Event Strategies. Mr. Hite graduated from Ithaca College with a B.S. in Organizational Communication, Learning, and Design and is a CFA Charter holder.

Mr. Hite is responsible for investment research in Large Cap Pharmaceutical, Large Cap Biotechnology and Medical Technology companies and serves as a member of the team responsible for making investments on behalf of the Funds.
CHRISTOPHER ABBOTT, Senior Analyst, Research
Chris Abbott joined TCM in June of 2016 as a Senior Analyst. Previously, Mr. Abbott spent 8 years at Leerink Partners where he was a Vice President on the Equity Research team covering the Healthcare IT and Healthcare Supply Chain group. Mr. Abbott’s research efforts also focused on Healthcare Strategy and Healthcare Policy during his time at Leerink. Mr. Abbott graduated from Hamilton College with a B.A. in Economics and a focus in Pre-Medical Studies. Mr. Abbott is responsible for investment research in healthcare services and healthcare facilities companies on behalf of the Funds.
LAURA WOODWARD, Chief Compliance Officer and Vice President of Fund Administration
Ms. Woodward joined HQCM in May of 2009 as Chief Compliance Officer and Vice President of Fund Administration. Ms. Woodward is also Secretary and Treasurer of the Funds. Previously, Ms. Woodward was a Senior Manager with PricewaterhouseCoopers LLP from 1990 to 2009. Ms. Woodward received a B.A. from Lafayette College. Ms. Woodward is a Certified Public Accountant licensed in Massachusetts.

Ms. Woodward is responsible for providing support for and participating in all functions provided by the Adviser to the Funds. Ms. Woodward is responsible for the administration of the fair valuation process to the extent that the Funds have delegated that duty to the Adviser, certain adviser financial and administrative functions, financial reporting, oversight of service providers and regulatory compliance matters. Ms. Woodward is also responsible for developing procedures and policies that are reasonably designed to ensure that the Funds operate in accordance with the Funds’ registration statements.

News & Analysis

You may also be interested in: